logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

ESMO 2020 extra: In HER2+ metastatic breast cancer, tucatinib doesn't degrade QoL

No differences between tucatinib and placebo in QoL on the EQ-5D-5L.